IDRx rais­es $120M for tar­get­ed GIST drug fol­low­ing lead­er­ship change

Un­der new lead­er­ship, IDRx has raised $120 mil­lion to push its tar­get­ed treat­ment for a rare di­ges­tive tract can­cer through ear­ly-stage stud­ies.

The com­pa­ny plans …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER